Table 2. Influence of clinicopathological characteristics on patient prognosis.
| Variables | n | DFS |
OS |
||||||
|---|---|---|---|---|---|---|---|---|---|
| 1-yr | 3-yr | 5-yr | P | 1-yr | 3-yr | 5-yr | P | ||
| Gender | |||||||||
| Male | 121 | 71.1% | 56.0% | 47.2% | 85.1% | 63.4% | 56.5% | ||
| Female | 9 | 77.8% | 66.7% | 66.7% | 0.382 | 88.9% | 77.8% | 77.8% | 0.539 |
| Age (years) | |||||||||
| ≤50 | 68 | 64.7% | 52.1% | 42.6% | 80.9% | 57.7% | 49.0% | ||
| >50 | 62 | 79.0% | 61.8% | 54.9% | 0.152 | 90.3% | 71.7% | 67.2% | 0.060 |
| HBsAg | |||||||||
| Positive | 119 | 72.3% | 57.9% | 49.1 | 85.7% | 65.6% | 58.5% | ||
| Negative | 11 | 63.6% | 42.4% | 42.4% | 0.402 | 81.8% | 63.6% | 54.5% | 0.780 |
| Child-Pugh stage | |||||||||
| A | 84 | 66.7% | 48.7% | 39.3% | 83.3% | 60.9% | 56.0% | ||
| B | 36 | 80.6% | 69.0% | 63.3% | 74.1% | 67.7% | 54.4% | ||
| C | 10 | 80.0% | 80.0% | 80.0% | 0.037 | 80.0% | 80.0% | 80.0% | 0.364 |
| Preoperative tumor therapy | |||||||||
| Yes | 59 | 72.9% | 53.1% | 50.7% | 86.4% | 66.3% | 52.6% | ||
| No | 71 | 70.4% | 59.8% | 52.0% | 0.580 | 84.5% | 62.8% | 60.9% | 0.960 |
| AFP (ng/ml) | |||||||||
| ≤400 | 82 | 84.1% | 72.5% | 60.7% | 92.7% | 77.5% | 70.8% | ||
| >400 | 48 | 75.0% | 29.6% | 26.3% | <0.001 | 72.9% | 41.7% | 36.4% | <0.001 |
| Size of largest tumor (cm) | |||||||||
| ≤5 | 74 | 86.5% | 75.3% | 71.2% | 95.9% | 84.2% | 78.6% | ||
| 5 to 8 | 22 | 68.2% | 38.4% | 25.6% | 77.3% | 54.2% | 36.9% | ||
| >8 | 34 | 41.2% | 26.7% | 16.7% | <0.001 | 67.6% | 29.4% | 29.4% | <0.001 |
| Tumor number | |||||||||
| ≤3 | 93 | 81.7% | 69.1% | 59.8% | 87.1% | 77.1% | 68.3% | ||
| >3 | 37 | 45.9% | 25.3% | 20.2% | <0.001 | 81.1% | 31.3% | 31.3% | <0.001 |
| Edmondson grading | |||||||||
| I–II | 86 | 73.3% | 55.1% | 46.4% | 87.2% | 65.9% | 55.7% | ||
| III–IV | 44 | 68.2% | 59.1% | 51.7% | 0.812 | 81.8% | 61.1% | 61.1% | 0.799 |
| Macro-vascular invasion | |||||||||
| Yes | 29 | 44.8% | 8.0% | 4.0% | 72.4% | 23.6% | 19.7% | ||
| No | 101 | 79.2% | 70.7% | 61.7% | <0.001 | 89.1% | 76.7% | 69.6% | <0.001 |
| Micro-vascular invasion | |||||||||
| Yes | 20 | 50.0% | 20.8% | 13.9% | 75.0% | 27.3% | 21.8% | ||
| No | 110 | 75.5% | 63.0% | 54.7% | <0.001 | 87.3% | 71.1% | 64.7% | <0.001 |
| γ-GGT (U/L) | |||||||||
| ≤128 | 77 | 81.8% | 70.7% | 63.4% | 93.5% | 78.6% | 75.1% | ||
| >128 | 53 | 56.6% | 35.5% | 32.0% | <0.001 | 73.6% | 43.8% | 34.3% | <0.001 |
| Milan criteria | |||||||||
| Within | 46 | 93.5% | 88.7% | 85.3% | 97.8% | 95.6% | 89.9% | ||
| Beyond | 84 | 59.5% | 38.5% | 28.5% | <0.001 | 78.6% | 47.3% | 40.8% | <0.001 |
| UCSF criteria | |||||||||
| Within | 69 | 91.3% | 80.4% | 78.1% | 94.2% | 89.5% | 81.9% | ||
| Beyond | 61 | 49.2% | 29.3% | 15.9% | <0.001 | 75.4% | 35.8% | 31.3% | <0.001 |
| Hangzhou criteria | |||||||||
| Within | 81 | 87.7% | 80.9% | 71.8% | 92.6% | 84.8% | 79.9% | ||
| Beyond | 49 | 44.9% | 16.3% | 10.2% | <0.001 | 73.5% | 31.4% | 24.2% | <0.001 |
DFS, disease-free survival; OS, overall survival; Other abbreviations as in Table 1.